Catherine Smith, MD

Levis MJ, Perl AE, Schiller GJ, Fathi AT, Roboz GJ, Wang ES, Altman JK, Rajkhowa T, Ando M, Suzuki T, Subach RA, Maier G, Madden T, Johansen M, Cheung K, Kurman M, Smith CC. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia. Blood advances 2024. PMID: 38502195

Wintering A, Hecht A, Meyer J, Wong EB, Hübner J, Abelson S, Feldman K, Kennedy VE, Peretz CAC, French DL, Maguire JA, Jobaliya C, Vasquez MR, Desai S, Dulman R, Nemecek E, Haines H, Hammad M, El Haddad A, Kogan SC, Abdullaev Z, Chehab FF, Tasian SK, Smith CC, Loh ML, Stieglitz E. LNK/SH2B3 as a novel driver in juvenile myelomonocytic leukemia. Haematologica 2023. PMID: 38152053

Kennedy VE, Smith CC. FLT3 targeting in the modern era: from clonal selection to combination therapies. International journal of hematology 2023. PMID: 38112995

Fieke W Hoff, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L Lin, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Uma M. Borate, Alice Mims, John C. Byrd, Yazan F. Madanat. Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial. Blood 2023. PMID:

Uma M. Borate, Ying Huang, Rina Li Welkie, Ronan T. Swords, Elie Traer, Eytan M. Stein, Tara L Lin, Yazan F. Madanat, Prapti A. Patel, Robert H. Collins, Maria R. Baer, Vu H. Duong, William Blum, Martha Arellano, Wendy Stock, Olatoyosi Odenike, Robert L. Redner, Tibor J. Kovacsovics, Michael W. Deininger, Joshua F. Zeidner, Rebecca Olin, Catherine C. Smith, James M. Foran, Gary J. Schiller, Emily K Curran, Kristin L Koenig, Nyla A. Heerema, Timothy Chen, Molly Martycz, Mona Stefanos, Sonja Gullen Marcus, Leonard Rosenberg, Brian J. Druker, Ross L Levine, Amy Burd, Ashley Owen Yocum, Alice Mims, John C. Byrd. Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial. Blood 2023. PMID:

Timothy T. Ferng, Samantha M. Pintar, Vanessa E. Kennedy, Theodore C. Tarver, Shaheen Kabir, Veronica Steri, Juan Antonio Camara Serrano, Fernando Salangsang, Paul Phojanakong, Juwita Hübner, Carolina E. Morales, Jose M. Rivera, Aaron C. Logan, Benjamin Braun, Elliot Stieglitz, Luke A. Gilbert, Catherine C. Smith. Mediator Kinase/CDK8 Inhibition As a Strategy to Improve FLT3 Inhibitor Activity in Acute Myeloid Leukemia. Blood 2023. PMID:

Vanessa E. Kennedy, Cheryl A C Peretz, Andrew Koh, Elaine Tran, Dalia Dhingra, Saurabh Gulati, Adam Sciambi, Olga Sala-Torra, Lan Beppu, Aaron C. Logan, Alexander Perl, Wendy Stock, Geoffrey L Uy, Ann-Kathrin Eisfeld, Jerald P. Radich, Catherine C. Smith. Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML). Blood 2023. PMID:

Bogdan Popescu, Elliot Stieglitz, Catherine C. Smith. RAS MULTI(ON) Inhibitor RMC-7977 Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 Inhibitors in AML Models. Blood 2023. PMID:

Cheryl A C Peretz, Elaine Tran, Bogdan Popescu, Vanessa E. Kennedy, Tanya Kumar, Lisa McGary, Natalie Tantisira, Eric Wong, Jose M. Rivera, Simayijiang Xirenayi, Elliot Stieglitz, Catherine C. Smith, Juwita Hübner. Threshold Attenuation of Perk Signaling Is Sufficient to Overcome RAS-Mediated FLT3 Inhibitor Resistance. Blood 2023. PMID:

Popescu B, Stahlhut C, Tarver TC, Wishner S, Lee BJ, Peretz CAC, Luck C, Phojanakong P, Camara Serrano JA, Hongo H, Rivera JM, Xirenayi S, Chukinas JA, Steri V, Tasian SK, Stieglitz E, Smith CC. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell reports. Medicine 2023. PMID: 37992684

Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano JAC, Salangsang F, Phojanakong P, McMillan M, Gavallos V, Leavitt AD, Logan AC, Rooney CM, Eyquem J, Sinz A, Huang BJ, Stieglitz E, Smith CC, Moritz RL, Sidhu SS, Huang L, Wiita AP. Structural surfaceomics reveals an AML-specific conformation of integrin ß2 as a CAR T cellular therapy target. Nature cancer 2023. PMID: 37904046

Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E. The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib. American journal of hematology 2023. PMID: 37815132

Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL. Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. Journal of geriatric oncology 2023. PMID: 37678052

Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žucenka A, Zeidan AM. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. The Lancet. Haematology 2023. PMID: 37572683

Catherine Choy Smith, Pankit Vachhani, Guillermo Garcia-Manero, Nicole Renee Grieselhuber, Guru Subramanian Guru Murthy, Astha Bhatia, Jatinder Arora, Hooman Izadi, Anthony Fiorino, Raajit Rampal. A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML). Journal of Clinical Oncology 2023. PMID:

Peretz CAC, Kennedy VE, Walia A, Delley CL, Koh A, Tran E, Clark IC, Hayford CE, D'Amato C, Xue Y, Fontanez KM, Roy R, Logan AC, Perl AE, Abate A, Olshen A, Smith CC. Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification. bioRxiv : the preprint server for biology 2023. PMID: 37292835

Clark IC, Fontanez KM, Meltzer RH, Xue Y, Hayford C, May-Zhang A, D'Amato C, Osman A, Zhang JQ, Hettige P, Ishibashi JSA, Delley CL, Weisgerber DW, Replogle JM, Jost M, Phong KT, Kennedy VE, Peretz CAC, Kim EA, Song S, Karlon W, Weissman JS, Smith CC, Gartner ZJ, Abate AR. Microfluidics-free single-cell genomics with templated emulsification. Nature biotechnology 2023. PMID: 36879006

Jerry Lee, Raja Rajalingam, Denice Kong, Weiyun Ai, Charalambos B. Andreadis, Lloyd E. Damon, Neil Dunavin, Karin M. Gaensler, Lawrence D. Kaplan, Thomas G. Martin, Rebecca L. Olin, Peter H. Sayre, Catherine C. Smith, Jeffrey L. Wolf, Aaron C. Logan. 304 HLA-DPB1 Mismatch Permissiveness and Activating KIR Haplotypes Have Different Impact on Allogeneic Hematopoietic Cell Transplant Survival Outcomes in Acute Leukemias and Myelodysplastic Syndrome. Transplantation and cellular therapy 2023. PMID:

Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022. PMID: 35849791

Timothy T. Ferng, Daisuke Terada, Makoto Ando, Theodore C. Tarver, Fihr Chaudhary, Kimberly C. Lin, Aaron C. Logan, Catherine C. Smith. Abstract LB516A: The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms. Cancer research 2022. PMID:

Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, Recher C, Smith CC, Levis MJ, Strickland S, Röllig C, Groß-Langenhoff M, Chou WC, Lee JH, Yokoyama H, Hasabou N, Lu Q, Tiu RV, Altman JK. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. TO REMOVE 2022. PMID: 35637252

Ferng TT, Terada D, Ando M, Tarver TC, Chaudhary F, Lin KC, Logan AC, Smith CC. The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. TO REMOVE 2022. PMID: 35395091

Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory AML patients in the phase 3 ADMIRAL study of gilteritinib. TO REMOVE 2022. PMID: 35130342

Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Huang CY, Olin RL. Patterns and predictors of functional decline after alloHCT in older adults. TO REMOVE 2022. PMID: 35247612

Bogdan Popescu, Carlos Stahlhut, Theodore C. Tarver, Timothy T. Ferng, Cheryl Peretz, Sydney Wishner, Paul Phojanakong, Veronica Steri, Eric B. Wong, Jose M. Rivera, Elliot Stieglitz, Catherine C. Smith. Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia. TO REMOVE 2021. PMID:

Kelly L. Schoenbeck, Anand Dhruva, Albert Lee, Neha G. Goyal, Adrienne K. Yang, Sa Ra Park, Catherine C. Smith, Neil P Shah, Chloe E. Atreya. Being Present-CML: A Distress Reduction Intervention for Patients with Chronic Myeloid Leukemia Taking Tyrosine Kinase Inhibitors. TO REMOVE 2021. PMID:

Timothy T. Ferng, Theodore C. Tarver, Shaheen Kabir, Benjamin Braun, Aaron C. Logan, Luke A. Gilbert, Catherine C. Smith. RNA Polymerase II Is a Therapeutic Target to Overcome FLT3 Inhibitor Resistance Mediated By the Bone Marrow Microenvironment. TO REMOVE 2021. PMID:

Cheryl A C Peretz, Vanessa E Kennedy, Rhonda E. Ries, Soheil Meshinchi, Catherine C. Smith. Single Cell Sequencing of Pediatric Acute Myeloid Leukemia Reveals Clonal Evolution to Relapse on Combination Chemotherapy with Sorafenib. TO REMOVE 2021. PMID:

Naval Daver, Alexander E. Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark R. Litzow, James McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Monique Dail, Satya Siddani, Jing Wang, Brenda Chyla, Paul Lee, Jessica K. Altman. Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia. TO REMOVE 2021. PMID:

Alexander E Perl, Jessica K Altman, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Catherine C Smith, Mark J Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu. AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Clinical Lymphoma Myeloma & Leukemia 2021. PMID:

Jessica K. Altman, Naval Daver, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James McCloskey, Catherine C. Smith, Gary Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Satya Siddani, Jing Wang, Paul Lee, Alexander E. Perl. AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study. Clinical Lymphoma Myeloma & Leukemia 2021. PMID:

James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical pharmacokinetics 2021. PMID: 34297319

Alexander E Perl, Jessica K Altman, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Catherine C Smith, Mark J Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu. Poster: AML-091: Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Clinical Lymphoma Myeloma & Leukemia 2021. PMID:

Jessica K. Altman, Naval Daver, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James McCloskey, Catherine C. Smith, Gary Schiller, Terrence Bradley, Ramon V. Tiu, Kiran Naqvi, Satya Siddani, Jing Wang, Paul Lee, Alexander E. Perl. Poster: AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study. Clinical Lymphoma Myeloma & Leukemia 2021. PMID:

Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica 2021. PMID: 33626861

Smith CC, Viny AD, Massi E, Kandoth C, Socci ND, Rapaport F, Najm M, Medina-Martinez JS, Papaemmanuil E, Tarver TC, Hsu HH, Le MH, West B, Bollag G, Taylor BS, Levine RL, Shah NP. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2021. PMID: 34103301

Mark J. Levis, Catherine Choy Smith, Alexander E. Perl, Gary J. Schiller, Amir Tahmasb Fathi, Gail J. Roboz, Eunice S. Wang, Jessica K. Altman, Makoto Ando, Takeaki Suzuki, Ruth Ann Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael R. Kurman. Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology 2021. PMID:

Demaree B, Delley CL, Vasudevan HN, Peretz CAC, Ruff D, Smith CC, Abate AR. Joint profiling of DNA and proteins in single cells to dissect genotype-phenotype associations in leukemia. Nature communications 2021. PMID: 33707421

Peretz CAC, McGary LHF, Kumar T, Jackson H, Jacob J, Durruthy-Durruthy R, Levis MJ, Perl A, Huang BJ, Smith CC. Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Blood advances 2021. PMID: 33666651

Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Frontiers in oncology 2020. PMID: 33425766

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ, Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet (London, England) 2020. PMID: 33220855

Alexander E. Perl, Jessica K. Altman, Naoko Hosono, Pau Montesinos, Nikolai A. Podoltsev, Giovanni Martinelli, Catherine C. Smith, Mark Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu. Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib. Blood 2020. PMID:

Kelly L. Schoenbeck, Sirisha Tummala, Neha G. Goyal, Catherine C. Smith, Neil P. Shah. Cognitive Dysfunction Associated with Tyrosine Kinase Inhibitors in Patients with CML in Chronic Phase. Blood 2020. PMID:

Amir T. Fathi, Alexander E. Perl, Mark Levis, Catherine C. Smith, Andrew M. Brunner, Koichi Takahashi, Philip C. Amrein, Hanno R. Hock, Gabriela S. Hobbs, Rupa Narayan, Jenna A. Moran, Meghan Bergeron, Julia E. Foster, Naval Daver, Courtney D. DiNardo. Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML). Blood 2020. PMID:

Naval Daver, Jessica K. Altman, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James K. McCloskey, Catherine C. Smith, Gary J. Schiller, Terrence Bradley, Ramon V. Tiu, Wan-Jen Hong, Bo Tong, Qin Qin, Kimberley Dilley, Alexander E. Perl. Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study. Blood 2020. PMID:

Kelly L. Schoenbeck, Sirisha Tummala, Rebecca L. Olin, Neha G. Goyal, Anand Dhruva, Lloyd E. Damon, Aaron C. Logan, Catherine C. Smith, Neil P. Shah. Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance. Blood 2020. PMID:

James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D, Kadokura T, Souda K, Patton M, Lu Z, Liu C, Moy S, Levis MJ, Bahceci E. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor. Clinical pharmacokinetics 2020. PMID: 32304015

Smith CC. FLT3 Inhibition in Acute Myeloid Leukemia. Clinical lymphoma, myeloma & leukemia 2020. PMID: 32862867

Smith CC, Levis MJ, Frankfurt O, Pagel JM, Roboz GJ, Stone RM, Wang ES, Severson PL, West BL, Le MH, Kayser S, Lam B, Hsu HH, Zhang C, Bollag G, Perl AE. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia. Blood advances 2020. PMID: 32330242

Tarver TC, Hill JE, Rahmat L, Perl AE, Bahceci E, Mori K, Smith CC. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood advances 2020. PMID: 32040554

Smith CC. The growing landscape of FLT3 inhibition in AML. Hematology. American Society of Hematology. Education Program 2019. PMID: 31808872

Benjamin Demaree, Cyrille Delley, Cheryl Peretz, Harish Vasudevan, David Ruff, Aik Ooi, Catherine C. Smith, Adam Abate. Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones. Blood 2019. PMID:

Kelly L. Schoenbeck, Giselle Salmasi, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Aaron C. Logan, Rebecca L. Olin, Andrew D. Leavitt, Catherine C. Smith. Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms. Blood 2019. PMID:

Varun Mittal, Mimi Lo, Lloyd E. Damon, Karin L. Gaensler, Thomas G. Martin, Rebecca L. Olin, Catherine C. Smith, Aaron C. Logan. Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood 2019. PMID:

Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Giovanni Martinelli, Andreas Neubauer, Ellin Berman, Pau Montesinos, Maria R. Baer, Richard A. Larson, Wen-Chien Chou, Hisayuki Yokoyama, Christian Recher, Sung-Soo Yoon, Jason E. Hill, Matt Rosales, Erkut Bahceci. Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood 2019. PMID:

Cheryl A Cohler Peretz, Lisa H F McGary, Tanya F Kumar, J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Chunxiao Zhang, Mark J. Levis, Alexander E. Perl, Anskar Yu Hung Leung, Catherine C. Smith. Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib. Blood 2019. PMID:

Kelly L. Schoenbeck, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Karin L. Gaensler, Andrew D. Leavitt, Aaron C. Logan, Gabriel N. Mannis, Rebecca L. Olin, Giselle Salmasi, Peter H. Sayre, Neil P. Shah, Anand Dhruva, Chloe E. Atreya, Catherine C. Smith. Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution. Blood 2019. PMID:

Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia 2019. PMID: 31511612

Huang LW, Sheng Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Steinman MA, Huang CY, Olin RL. Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplant recipients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2019. PMID: 31493541

Catherine C. Smith. Use of FLT3 Inhibitors in AML. Clinical Lymphoma Myeloma & Leukemia 2019. PMID:

McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJ, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE. Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer discovery 2019. PMID: 31088841

Smith CC. Roman warfare: targeting of support cells in AML. Blood 2019. PMID: 30733203

Li-Wen Huang, Chiung-Yu Huang, Charalambos Andreadis, Aaron C. Logan, Gabriel N. Mannis, Catherine C. Smith, Karin M. Gaensler, Thomas G. Martin, Lloyd E. Damon, Michael A. Steinman, Rebecca L. Olin. Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies. Blood 2018. PMID:

Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Catherine C. Smith, Maria R. Baer, David F. Claxton, Joseph G. Jurcic, Ellen K. Ritchie, Stephen A. Strickland, Raoul Tibes, Jason E. Hill, Matt Rosales, Erkut Bahceci. Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leuke Blood 2018. PMID:

Dennis J. Eastburn, Christine M. McMahon, Robert Durruthy-Durruthy, Martin Carroll, Catherine C. Smith, Alexander E. Perl. Longitudinal Monitoring of AML Tumors with High-Throughput Single-Cell DNA Sequencing Reveals Rare Clones Prognostic for Disease Progression and Therapy Response. Blood 2018. PMID:

Cortes J, Perl AE, Döhner H, Kantarjian H, Martinelli G, Kovacsovics T, Rousselot P, Steffen B, Dombret H, Estey E, Strickland S, Altman JK, Baldus CD, Burnett A, Krämer A, Russell N, Shah NP, Smith CC, Wang ES, Ifrah N, Gammon G, Trone D, Lazzaretto D, Levis M. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. The Lancet. Oncology 2018. PMID: 29859851

Mark J. Levis, Catherine Choy Smith, Koji Ishizuka, Ken Kobayashi, Meena Arunachalam, Yibin Wang, Deborah Lazzaretto, Jorge E. Cortes. Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3 -ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment. Journal of Clinical Oncology 2018. PMID:

Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, Claxton D, Erba HP, Gill S, Goldberg S, Jurcic JG, Larson RA, Liu C, Ritchie E, Schiller G, Spira AI, Strickland SA, Tibes R, Ustun C, Wang ES, Stuart R, Röllig C, Neubauer A, Martinelli G, Bahceci E, Levis M. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. The Lancet. Oncology 2017. PMID: 28645776

Jessica K. Altman, Alexander E. Perl, Jorge E. Cortes, Catherine Choy Smith, Mark Robert Litzow, Jason E Hill, Richard A. Larson, Charles Liu, Ellen K. Ritchie, Stephen Anthony Strickland, Eunice S. Wang, Andreas Neubauer, Giovanni Martinelli, Erkut Bahceci, Mark J. Levis. Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Journal of Clinical Oncology 2017. PMID:

Smith CC, Paguirigan A, Jeschke GR, Lin KC, Massi E, Tarver T, Chin CS, Asthana S, Olshen A, Travers KJ, Wang S, Levis MJ, Perl AE, Radich JP, Shah NP. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. Blood 2017. PMID: 28490572

Catherine Choy Smith, Mark J. Levis, Mark Robert Litzow, Alexander E. Perl, Jessica K. Altman, Stan Gill, Geoffrey Yuen, Peter Bonate, Takeshi Kadokura, Angela Joubert James, Charles Liu, Itsuro Nagase, Ogert Fisniku, Erkut Bahceci. Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology 2016. PMID:

Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI insight 2016. PMID: 27158668

Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Volume 57 of Issue 7. Leukemia & lymphoma 2016. PMID: 26490487

Timothy Ferng, Catherine Choy Smith. Resistance to FLT3 Inhibitors. Resistance to Tyrosine Kinase Inhibitors 2016. PMID:

Thai Hoa Tran, Jonathan Van Nguyen, Catherine C. Smith, Kathryn G. Roberts, Charles G. Mullighan, Neil P. Shah, Mignon L. Loh. Identifying Drug-Resistant Mutations in Ebf1-Pdgfrb Ph-like Acute Lymphoblastic Leukemia. Blood 2015. PMID:

Catherine C. Smith, Mark J. Levis, Mark R Litzow, Alexander E. Perl, Jessica K. Altman, Stanley C. Gill, Takeshi Kadokura, Geoffrey J. Yuen, Ogert Fisniku, Charles Liu, Itsuro Nagase, Briana Sargent, Noreen Welter, Erkut Bahceci. Pharmacokinetic Profile and Pharmacodynamic Effects of ASP2215, a Selective, Potent Inhibitor of FLT3/AXL, in Patients with Relapsed or Refractory Acute Myeloid Leukemia: Results from a First-in-Human Phase 1/2 Study. Blood 2015. PMID:

Catherine C. Smith, Aaron D. Viny, Evan S. Massi, Cyriac Kandoth, Nicholas D. Socci, Henry Hsu, Brian West, Gideon Bollag, Barry S. Taylor, Ross L. Levine, Neil P. Shah. Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors. Blood 2015. PMID:

Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Jorge E. Cortes, Ellen K. Ritchie, Richard A. Larson, Catherine Choy Smith, Eunice S. Wang, Stephen Anthony Strickland, Maria R. Baer, Mark Robert Litzow, David Claxton, Gary J. Schiller, Celalettin Ustun, Charles Liu, Stan Gill, Briana Sargent, Erkut Bahceci. Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). Journal of Clinical Oncology 2015. PMID:

Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP. Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. Cancer discovery 2015. PMID: 25847190

Frett B, McConnell N, Smith CC, Wang Y, Shah NP, Li HY. Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. European journal of medicinal chemistry 2015. PMID: 25765758

Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Volume 15 of Issue 6. Clinical lymphoma, myeloma & leukemia 2015. PMID: 25776193

Gabriel N. Mannis, Thomas G. Martin, Lloyd E. Damon, Aaron C. Logan, Weiyun Ai, Karin M.L. Gaensler, Lawrence D. Kaplan, Anuj Mahindra, Rebecca L. Olin, Peter Sayre, Catherine C. Smith, Jeffrey L. Wolf, Jimmy Hwang, Charalambos Andreadis. Long-Term Outcomes of 133 Patients with Intermediate-Risk Acute Myeloid Leukemia Treated with High-Dose Chemotherapy and Autologous Stem Cell Rescue in First Complete Remission. Biology of Blood and Marrow Transplantation 2015. PMID:

Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY, Smith CC, Shah NP, Shokat KM. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. eLife 2014. PMID: 25531068

Katherine A Minson, Catherine C Smith, Alisa B. Lee-Sherick, Deborah DeRyckere, Elisabeth Lasater, Amanda A. Hill, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Neil P. Shah, Douglas K. Graham. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia. Blood 2014. PMID:

Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell reports 2014. PMID: 25456130

Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. Journal of geriatric oncology 2014. PMID: 24894413

Sudhindra A, Smith CC. FLT3 inhibitors in AML: are we there yet? Current hematologic malignancy reports 2014. PMID: 24682858

Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, Kogan SC, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proceedings of the National Academy of Sciences of the United States of America 2014. PMID: 24623852

Gabriel N. Mannis, Lloyd E. Damon, Weiyun Ai, Charalambos Andreadis, Karin ML. Gaensler, Lawrence D. Kaplan, Aaron C. Logan, Anuj Mahindra, Rebecca L. Olin, Peter Sayre, Catherine C. Smith, Jeffrey M. Venstrom, Jeffrey L. Wolf, Thomas G. Martin. A Phase 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative Therapy for Autologous Stem Cell Transplant in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation 2014. PMID:

Rebecca L. Olin, Charalambos Andreadis, Thomas G. Martin, Jeffrey L. Wolf, Lawrence D. Kaplan, Weiyun Ai, Jeffrey M. Venstrom, Aaron C. Logan, Catherine C. Smith, Karin ML. Gaensler, Jimmy Hwang, Lloyd E. Damon. Comprehensive Geriatric Assessment Identifies Significant Functional Impairments in Older Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation 2014. PMID:

Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia research 2013. PMID: 24374145

Smith CC. Disease diversity and FLT3 mutations. Proceedings of the National Academy of Sciences of the United States of America 2013. PMID: 24324154

Gabriel N. Mannis, Lloyd E Damon, Weiyun Z. Ai, Charalambos Andreadis, Karin ML Gaensler, Neel K. Gupta, Lawrence D. Kaplan, Andrew D. Leavitt, Aaron C. Logan, Rebecca L. Olin, Peter H. Sayre, Catherine C Smith, Jeffrey M Venstrom, Thomas G Martin. Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia. Blood 2013. PMID:

Kimberly Lin, Catherine C Smith, Sara Salerno, Neil P. Shah. Mutations At The FLT3 Activation Loop D835 Residue Confer Differential Resistance To Clinically Active FLT3 Inhibitors. Blood 2013. PMID:

Catherine C Smith, Kimberly Lin, Elisabeth Lasater, Whitney Stewart, Lauren E Damon, Andrew Kasarskis, Ali Bashir, Matthew Pendleton, Robert Sebra, Alexander E Perl, Mai H Le, Chao Zhang, Brian West, Neil P. Shah. Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML). Blood 2013. PMID:

Collins BH, Holzknecht ZE, Lynn KA, Sempowski GD, Smith CC, Liu S, Parker W, Rockey DC. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver international : official journal of the International Association for the Study of the Liver 2013. PMID: 23710620

Catherine C. Smith, Neil P. Shah. The Role of Kinase Inhibitors in the Treatment of Patients with Acute Myeloid Leukemia. American Society of Clinical Oncology Educational Book 2013. PMID:

Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013. PMID: 23430109

Jesse W. Keller, Lloyd E. Damon, Lawrence D. Kaplan, Thomas G. Martin, Jeffrey L. Wolf, Weiyun Z. Ai, Charalambos Andreadis, Jeffrey M. Venstrom, Catherine C. Smith, Karin M.L. Gaensler, Jimmy Hwang, Rebecca L. Olin. Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Is Predictive of Serious Adverse Events and Overall Survival in Older Allogeneic Transplant Recipients. Biology of Blood and Marrow Transplantation 2013. PMID:

Smith CC, Shah NP. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013. PMID: 23714533

Willard Cheng, Elisabeth Lasater, Catherine C Smith, Mouanoutoua Mokang, Yun Bao, Neil Shah. Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples. Blood 2012. PMID:

Catherine C Smith, Jason Chin, Elisabeth Lasater, Amy L. Paguirigan, Kimberly Lin, Whitney Stewart, Sara Salerno, Lauren E Damon, Mark J. Levis, Alexander E Perl, Kevin Travers, Andrew Kasarskis, Jerald P. Radich, Neil Shah. Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220. Blood 2012. PMID:

Catherine C Smith, Elisabeth Lasater, Melissa Mccreery, Kimberly Lin, Whitney Stewart, Lauren E Damon, Alexander E Perl, Grace R Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, Neil Shah. Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants. Blood 2012. PMID:

Catherine C Smith, Michael Brown, Wendy T Parker, Kimberly Lin, Kevin Travers, Susana Wang, Susan Branford, Neil Shah. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy. Blood 2012. PMID:

Alexander E Perl, Grace R Jeschke, Catherine C Smith, James K. Mangan, Selina M. Luger, Martin Carroll. Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance. Blood 2012. PMID:

Catherine C. Smith, Neil P. Shah. Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia. American Society of Clinical Oncology Educational Book 2012. PMID:

Elisabeth A. Lasater, Catherine C. Smith, Neil P. Shah. Abstract 1893: Activating NRAS mutations are associated with FLT3-independent resistance to the clinically active FLT3 inhibitor AC220 in vitro. Experimental and Molecular Therapeutics 2012. PMID:

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012. PMID: 22504184

Smith CC, Shah NP. Mechanisms of resistance to targeted therapies in acute myeloid leukemia and chronic myeloid leukemia. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2012. PMID: 24451819

Jorge E. Cortes, Alexander E Perl, Catherine C. Smith, Tibor Kovacsovics, Herve Dombret, Hartmut Dohner, Bjorn Steffen, Arnaud Pigneux, Philippe Rousselot, Juergen Krauter, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Anthony D. Ho, Norbert Ifrah, Theo de Witt, Robert Corringham, Joyce James, David Lilienfeld, Eugen Leo, Guy Gammon, Mark J. Levis. A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results. Blood 2011. PMID:

Warren Fiskus, Catherine C. Smith, Jacqueline Smith, Scott C. Wise, Elisabeth Lasater, Lauren E. Damon, Sara Salerno, Allan Fleming, Ruben Reyes, Siddhartha Ganguly, Mark S. Berger, Tom J. Rutkoski, Joseph McGuirk, Neil Shah, Kapil N. Bhalla. Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations. Blood 2011. PMID:

Catherine C. Smith, Lauren E. Damon, Xiaotian Zhu, Sara Salerno, Neil Shah. Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants. Blood 2011. PMID:

Catherine C. Smith, Alexander E Perl, Elisabeth Lasater, Chao Zhang, Grace R Jeschke, Lauren E. Damon, Martin Carroll, Neil P. Shah. PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro. Blood 2011. PMID:

Alexander E Perl, Grace R Jeschke, Catherine C. Smith, James K. Mangan, Selina M. Luger, Martin Carroll. Phospho-Specific Flow Cytometry of Fixed Whole Blood Demonstrates In Vivo FLT3 Inhibition in Circulating Leukemic Blasts During AC220 Therapy and Accurately Detects the Development of Therapeutic Resistance,. Blood 2011. PMID:

Catherine C. Smith, Michael Brown, Jason Chin, Corynn Kasap, Sara Salerno, Lauren E. Damon, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, Neil Shah. Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,. Blood 2011. PMID:

Catherine C. Smith, Jason Chin, Qi Wang, Sara Salerno, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, Alexander E Perl, Kevin Travers, Susana Wang, Andrew Kasarskis, Eric Schadt, John Kuriyan, Neil Shah. Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia. Blood 2011. PMID:

Smith CC, Shah NP. Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 2011. PMID: 21948230

Catherine C. Smith, Lauren Damon, Sara Salerno, Neil P. Shah. Abstract 4737: Saturation mutagenesis of FLT3-ITD: AC220-resistance-conferring kinase domain mutations are restricted to a limited number of residues and are cross-resistant to sorafenib in vitro. Experimental and Molecular Therapeutics 2011. PMID:

Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology. American Society of Hematology. Education Program 2011. PMID: 22160023

Kaimal AJ, Smith CC, Laros RK, Caughey AB, Cheng YW. Cost-effectiveness of private umbilical cord blood banking. Obstetrics and gynecology 2009. PMID: 19888044

Matusik E, Gibson TP. Fluorometric assay for N-acetylprocainamide. Clinical chemistry 1975. PMID: 160

Rusch G, Chaker RB. [The analgesic efficacy of pentazocine (fortalgesic winthrop) in suppositories with postoperative pains (author's transl)]. Therapeutische Umschau. Revue therapeutique 1975. PMID: 7026

Smith RJ, Bryant RG. Metal substitutions incarbonic anhydrase: a halide ion probe study. Biochemical and biophysical research communications 1975. PMID: 3